202 related articles for article (PubMed ID: 28800127)
41. Biophysical characterization of the b-HLH-LZ of ΔMax, an alternatively spliced isoform of Max found in tumor cells: Towards the validation of a tumor suppressor role for the Max homodimers.
Maltais L; Montagne M; Bédard M; Tremblay C; Soucek L; Lavigne P
PLoS One; 2017; 12(3):e0174413. PubMed ID: 28350847
[TBL] [Abstract][Full Text] [Related]
42. Mnt: master regulator of the Max network.
Nilsson JA; Cleveland JL
Cell Cycle; 2004 May; 3(5):588-90. PubMed ID: 15107624
[TBL] [Abstract][Full Text] [Related]
43. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
Schaub FX; Dhankani V; Berger AC; Trivedi M; Richardson AB; Shaw R; Zhao W; Zhang X; Ventura A; Liu Y; Ayer DE; Hurlin PJ; Cherniack AD; Eisenman RN; Bernard B; Grandori C;
Cell Syst; 2018 Mar; 6(3):282-300.e2. PubMed ID: 29596783
[TBL] [Abstract][Full Text] [Related]
44. Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs.
Happo L; Phipson B; Smyth GK; Strasser A; Scott CL
Cell Death Dis; 2012 May; 3(5):e306. PubMed ID: 22573037
[TBL] [Abstract][Full Text] [Related]
45. Lessons learned from Myc/Max/Mad knockout mice.
Pirity M; Blanck JK; Schreiber-Agus N
Curr Top Microbiol Immunol; 2006; 302():205-34. PubMed ID: 16620030
[TBL] [Abstract][Full Text] [Related]
46. The E-box binding factors Max/Mnt, MITF, and USF1 act coordinately with FoxO to regulate expression of proapoptotic and cell cycle control genes by phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 signaling.
Terragni J; Nayak G; Banerjee S; Medrano JL; Graham JR; Brennan JF; Sepulveda S; Cooper GM
J Biol Chem; 2011 Oct; 286(42):36215-27. PubMed ID: 21873430
[TBL] [Abstract][Full Text] [Related]
47. Kinetics of myc-max-mad gene expression during hepatocyte proliferation in vivo: Differential regulation of mad family and stress-mediated induction of c-myc.
Mauleon I; Lombard MN; Muñoz-Alonso MJ; Cañelles M; Leon J
Mol Carcinog; 2004 Feb; 39(2):85-90. PubMed ID: 14750213
[TBL] [Abstract][Full Text] [Related]
48. Structural aspects of interactions within the Myc/Max/Mad network.
Nair SK; Burley SK
Curr Top Microbiol Immunol; 2006; 302():123-43. PubMed ID: 16620027
[TBL] [Abstract][Full Text] [Related]
49. Transcriptional Activation of MYC-Induced Genes by GCN5 Promotes B-cell Lymphomagenesis.
Farria AT; Plummer JB; Salinger AP; Shen J; Lin K; Lu Y; McBride KM; Koutelou E; Dent SYR
Cancer Res; 2020 Dec; 80(24):5543-5553. PubMed ID: 33168647
[TBL] [Abstract][Full Text] [Related]
50. Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo.
James L; Eisenman RN
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10429-34. PubMed ID: 12149476
[TBL] [Abstract][Full Text] [Related]
51. Dynamic in vivo interactions among Myc network members.
Yin X; Landay MF; Han W; Levitan ES; Watkins SC; Levenson RM; Farkas DL; Prochownik EV
Oncogene; 2001 Aug; 20(34):4650-64. PubMed ID: 11498788
[TBL] [Abstract][Full Text] [Related]
52. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC.
Smith DP; Bath ML; Harris AW; Cory S
Oncogene; 2005 May; 24(22):3544-53. PubMed ID: 15688022
[TBL] [Abstract][Full Text] [Related]
53. Polycomb group ring finger protein 6 suppresses Myc-induced lymphomagenesis.
Tanaskovic N; Dalsass M; Filipuzzi M; Ceccotti G; Verrecchia A; Nicoli P; Doni M; Olivero D; Pasini D; Koseki H; Sabò A; Bisso A; Amati B
Life Sci Alliance; 2022 Aug; 5(8):. PubMed ID: 35422437
[TBL] [Abstract][Full Text] [Related]
54. MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.
Chan KI; Zhang S; Li G; Xu Y; Cui L; Wang Y; Su H; Tan W; Zhong Z
Aging Dis; 2024 Apr; 15(2):640-697. PubMed ID: 37450923
[TBL] [Abstract][Full Text] [Related]
55. Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene.
Demma MJ; Mapelli C; Sun A; Bodea S; Ruprecht B; Javaid S; Wiswell D; Muise E; Chen S; Zelina J; Orvieto F; Santoprete A; Altezza S; Tucci F; Escandon E; Hall B; Ray K; Walji A; O'Neil J
Mol Cell Biol; 2019 Nov; 39(22):. PubMed ID: 31501275
[TBL] [Abstract][Full Text] [Related]
56. The MYCL and MXD1 transcription factors regulate the fitness of murine dendritic cells.
Anderson DA; Murphy TL; Eisenman RN; Murphy KM
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4885-4893. PubMed ID: 32071205
[TBL] [Abstract][Full Text] [Related]
57. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association.
Mao B; Zhao G; Lv X; Chen HZ; Xue Z; Yang B; Liu DP; Liang CC
Int J Biochem Cell Biol; 2011 Nov; 43(11):1573-81. PubMed ID: 21807113
[TBL] [Abstract][Full Text] [Related]
58. An MXD1-derived repressor peptide identifies noncoding mediators of MYC-driven cell proliferation.
Raffeiner P; Hart JR; García-Caballero D; Bar-Peled L; Weinberg MS; Vogt PK
Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6571-6579. PubMed ID: 32156728
[TBL] [Abstract][Full Text] [Related]
59. Design and properties of a Myc derivative that efficiently homodimerizes.
Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
[TBL] [Abstract][Full Text] [Related]
60. c-MYC targets the central oscillator gene Per1 and is regulated by the circadian clock at the post-transcriptional level.
Repouskou A; Prombona A
Biochim Biophys Acta; 2016 Apr; 1859(4):541-52. PubMed ID: 26850841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
